|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29.07.26 - 13:06
|
Ionis reports second quarter 2026 financial results and highlights progress on key programs (Business Wire)
|
|
|
- TRYNGOLZA® (olezarsen) demonstrating early sHTG launch momentum, underscoring multi-billion-dollar revenue potential in large patient population –
- Completed enrollment in Phase 3 REVEAL trial in Angelman syndrome -
- On track to achieve 2026 financial guidance -CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the second quarter ended June 30, 2026.
“With the approval of TRYNGOLZA in late June, Ionis is bringing the first and only treatment to reduce triglycerides and acute pancreatitis to people living with severe hypertriglyceridemia. We are encouraged by the early launch momentum and look forward to accelerating growth from TRYNGOLZA and our other wholly owned medicines in the quarters and years to come,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “In the second half of this year, we expect multiple important milestones, including approval of zilganersen for Alex...
|
|
|
29.07.26 - 13:06
|
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire (Business Wire)
|
|
|
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Frank Bennett, Ph.D., executive vice president and chief scientific officer, will retire effective February 2027.“As a founding scientist, Frank has been instrumental in shaping Ionis and advancing the entire field of RNA-targeted medicines,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “Frank's profound contributions include pioneering the use of antisense medicines in neurological disease. He led the discovery and development of the first approved medicines for spinal muscular atrophy and a genetic form of amyotrophic lateral sclerosis, which have transformed the lives of thousands of people. We are deeply grateful for Frank's scientific leadership and unwavering dedication to the patients and communities that are counting on us.”Dr. Bennett joined Ionis as a founding scientist in 1989 and has pioneered the use of antisense oligonucleotides (ASOs) across multiple therapeutic discip...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
